Publications

Title

Author

Year

Projected population level impact and cost-effectiveness of clinic and community-based tuberculosis screening approaches.

MCCREESH, N; Khan, PY; Yoon, I; Govender, I; Sithole, M; HOUBEN, RM G J; WHITE, RG; Grant, AD; SWEENEY, S;

2026

PLOS global public health, (2026).6 9 10.1371/journal.pgph.0006738.

Multimorbidity and health-related quality of life after tuberculosis treatment in Zimbabwe: A cross-sectional study with household comparators.

CALDERWOOD, CJ; Marambire, ET; Musunzuru, T; Madziva, K; Kavenga, F; Muringi, E; DIXON, J; Mutsvangwa, J; Gregson, CL; FERRAND, RA; FIELDING, K; KRANZER, K;

2026

PLOS global public health, (2026).6 9 10.1371/journal.pgph.0007119.

Evaluating the acceptability, feasibility, and implementation fidelity of a multipurpose mobile health (mHealth) app used for Tuberculosis (TB) contact tracing by Ward-Based Outreach Teams (WBOTs) in South Africa.

Mudzengi, DL; Tsope, L; Hippner, P; Mboniswa, F; Mpanza, T; Dube, T; Lessells, R; Govender, I; Gumede, D; GRANT, AD; Fielding, K; Chetty-Makkan, CM; Velen, K; Charalambous, S;

2026

PLOS global public health, (2026).6 8 10.1371/journal.pgph.0007120.

Evaluating the influence of vaccine archetypes and epidemiological conditions on clinical trial metrics for tuberculosis vaccine candidates.

Andrews, JR; Hermans, S; WHITE, RG; García-Basteiro, AL; Croda, J; Cobelens, F;

2026

Vaccine, (2026).91, 10.1016/j.vaccine.2026.129097.

Type 2 diabetes reshapes the B-cell compartment in tuberculosis, with reduction of transitional B cells and expansion of plasmablasts.

Petrone, L; Najafi-Fard, S; Altera, AM G; Aiello, A; Cuzzi, G; Farroni, C; Petruccioli, E; Vanini, V; Salmi, A; Barbarossa, G; Pajno, MC; Scolieri, P; DOCKRELL, HM; Joosten, SA; Mellini, V; Palmieri, F; Gualano, G; Goletti, D; INMI TB-T2D Study Group,;

2026

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, (2026).172, 10.1016/j.ijid.2026.109083.

Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine.

Wattiau, P; Omar, SV; Joseph, L; Demoitié, M-A; Gilbert, M; AYLES, HM; Diacon, AH; Ginsberg, AM; Hatherill, M; Hellström, E; Innes, JC; Malahleha, M; Martinson, N; Muyoyeta, M; Nduba, V; Tait, DR; Wilkinson, RJ; Roman, F;

2026

The Journal of infectious diseases (2026). 10.1093/infdis/jiag428.

Cohort profile: the Entebbe Mother and Baby Study (EMaBS).

WEBB, EL; Walusimbi, B; Komata, R; ELLIOTT, AM; The EMaBS Study Team,;

2026

BMJ open, (2026).16 8 10.1136/bmjopen-2026-118325.

Implications of edge cases for antimicrobial susceptibility predictions for rifampin, delamanid, and pretomanid with the WHO Mycobacterium tuberculosis mutation catalog.

Hermans, N; PHELAN, J; Sorrentino, R; Boysen, F; Sherry, NL; Miotto, P; Cirillo, DM; Chindelevitch, L; Rodwell, TC; Barilar, I; Niemann, S; Andres, S; Mischnik, A; Horan, K; Bond, K; Globan, M; Rubinstein, M; Losev, Y; CLARK, TG; Mitarai, S; Iskakova, A; Slyzkyi, A; Köser, CU; Kremer, K; Anthony, R;

2026

Microbiology spectrum (2026). 10.1128/spectrum.01821-26.

Tuberculosis policy should shift focus to population-level interventions for greatest impact.

Horton, KC; SCHWALB, A; HARKER, MJ; Goscé, L; Venero-Garcia, E; O'Brien, L; Gun, A; Sumner, T; MCQUAID, CF; Clark, RA; Prys-Jones, TO; Bakker, R; Liu, YE; Kubjane, M; Lienhardt, C; WHITE, RG; HOUBEN, RM G J;

2026

Nature health (2026). 10.1038/s44360-026-00197-9.

Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants: a multicentre, double-blind, randomised, phase 3, non-inferiority trial.

Nduba, V; Mathebula, M; Nankabirwa, V; Dempster, M; Mhimbira, F; Sabi, I; WAJJA, A; Cotton, MF; Barnabas, S; Adegnika, AA; Kaufmann, SH E; Brückner, S; May, M; Höß, CW; Revathy, M; Niranjan, V; Bhargava, A; Gupta, M; Kapse, D; Desai, S; Grode, L; Kulkarni, PS; Shaligram, U; PriMe consortium,;

2026

The Lancet. Infectious diseases (2026). 10.1016/s1473-3099(26)00374-9.